Innovation for industry | Health ＆ life sciences
Pain relief for a rapid return to normal activities and better quality of life.
Sublimed relieves chronic pain associated with osteoarthritis of the knee using a discreet and flexible transcutaneous neurostimulation patch. It is available in France and several European countries.
Transcutaneous electrical neurostimulation has been used for 30 years to fight chronic pain. It inhibits pain signals and triggers the secretion of endorphins, the body’s natural analgesics. However, conventional equipment is cumbersome and impractical; 40% of patients give up using it for practicality reasons.The startup Sublimed, born from the meeting between a CEA engineer and a pain center doctor, now offers a lightweight, miniaturized, and discreet device controlled via smartphone. A clinical study carried out on 110 patients confirmed its effectiveness for osteoarthritis of the knee, a result that led France’s national health insurance provider to approve the device for reimbursement. Thanks to a web platform, the patient can find their neurostimulation data and track quality of life indicators like sleep and resumption of walking and other daily activities.Sublimed is based on a portfolio of six patents, including five CEA patents under license. It is collaborating with university medical centers to improve its technology and has been FDA-approved for the US market since 2021.
More than 20,000 patients in France have already used the actiTENS solution developed by Sublimed.
Year founded: 2015Originating institute: CEA-Liten
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.